Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Interest Income

Income earned on cash, deposits, and investments held by the company.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.

Context

  • Interest income increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Income vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
LRMR Competitors
Interest Income for LRMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$10.41M USD-19.3%+56.7%4.8%
ALTAltimmune, Inc.LTM Mar 2026$8.9M USD+23.5%+38.0%24713.9%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$8.6M USD-44.4%+152.5%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$7.09M USD-0.4%+66.6%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$6.34M USD-30.5%+286.9%—
ENGNenGene Holdings Inc.LTM Apr 2026$4.29M USD-63.1%+318.1%—
DBVTDBV Technologies S.A.LTM Mar 2026$2.21M USD+39.7%+14.0%—
ACIUAC Immune S.A.LTM Mar 2026CHF 1.36M CHF-58.3%+200.1%36.6%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
ANNXAnnexon, Inc.LTM Mar 2026-$1.14M USD-107.3%+38.6%—
Peer median (excluding LRMR) —-30.5%+66.6%20.7%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development38.4M24.25M27.67M73.28M154.22M
Selling, General & Admin12.07M12.28M14.09M17.61M18.27M
Operating Expenses50.47M36.53M41.76M90.89M172.5M
Depreciation & Amortization326K318K311K318K350K
EBITDA(50.31M)(35.04M)(36.64M)(80.29M)(165.32M)
EBITDA Margin—————
Operating Income(50.47M)(36.53M)(41.76M)(90.89M)(172.5M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses(171K)1.17M4.81M10.29M6.82M
Income Before Tax(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Net Margin—————
EPS (Basic)(2.93)(1.33)(0.84)(1.32)(2.27)
EPS (Diluted)(2.93)(1.33)(0.84)(1.32)(2.27)
Weighted Avg Shares17.16M25.76M43.9M61.26M72.95M
Weighted Avg Shares (Diluted)17.16M25.76M43.9M61.26M72.95M

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.